FDA Inspections: All-Time Audit Readiness, Data Integrity Culture, and Why You Cannot Prepare for an Inspection
Dr. Abhay Gaitonde — a senior pharma quality leader — on why inspection preparation is the wrong framing, why data integrity is a cultural problem, and the unresolved challenge of validating self-learning AI.
Vivek Gera Host
Co-founder · Leucine
Dr. Abhay Gaitonde
Quality Leader · Pharmaceutical Industry
About this episode
Vivek Gera speaks with Dr. Abhay Gaitonde, a senior pharmaceutical quality leader, about what FDA inspectors are actually looking for beyond textbook compliance — and why the concept of inspection preparation is fundamentally flawed. Dr. Abhay Gaitonde traces the 15-year shift in FDA inspection focus from facility readiness to data integrity to audit trails and now to cleaning validation, and argues that data integrity will never fully be resolved because it is a cultural problem rooted in the Jugaad mentality. The episode closes with a sharp unresolved question that Dr. Abhay Gaitonde poses to the audience: how do you validate self-learning AI, which by definition is different a year from now than it was when you first validated it?
Topics
Key takeaways
- There is no such thing as inspection preparation — you cannot do something different the day of the inspection; the only way to prepare is to do the right thing every single day, like going to the gym
- Data integrity is a cultural problem: the Jugaad mentality — workarounds glorified as heroic — is fundamentally incompatible with GMP, where you must do what you write and write what you do
- FDA inspection focus has shifted over 15 years: facility readiness → data integrity → production audit trails → and now, cleaning validation is the dominant issue across the industry
- Compliance is not a burden vs. productivity trade-off — the choice is between the burden of compliance and the burden of remediation; remediation is always more expensive
- AI is not up for debate as a useful tool — the real challenge is adopting it to maximise the gain, and ensuring humans still apply judgment to AI outputs rather than rubber-stamping them
- Self-learning AI poses an unresolved validation challenge: unlike static software validated once, AI changes over time — and the industry has no clear framework yet for revalidation frequency or scope
Powered by
FDA Tracker
Real-time tracking of FDA Warning Letters, 483s, Import Alerts, and Recalls.
Explore FDA TrackerSee how Leucine's AI-native platform is transforming pharmaceutical quality and manufacturing operations.
